Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosion USA to Start US Phase II Trials of Novel Candidate for Asthma

publication date: Apr 5, 2023

Biosion USA was given the green light to begin a US Phase II trial of its lead asset, BSI-045B, an anti-TSLP mAb, to treat atopic dermatitis, severe asthma and other eosinophilic and Th2 immune-related diseases. Biosion Inc., the parent company, is located in Nanjing and Delaware. In a Phase I trial, BSI-045B showed it could become a first-in-class treatment for AD based on its single dose activity in AD patients. Biosion out-licensed China rights for BSI-045B to CTTQ, a Sino Biopharm subsidiary, that is currently in a China Phase II trial for severe asthma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here